BPC-157 Use Is Climbing While Its Human Safety Data Isn't

More than 1,000 people have told their doctors since 2020 that they use BPC-157, according to an unpublished analysis of millions of de-identified health records reported by KFF Health News — and that count is rising fastest among young men. BPC-157 has no FDA-approved human use of any kind. It has also, by multiple researchers' accounting, barely been tested in humans at all.

That gap between how widely a compound is used and how little is known about it in people is the real story behind the peptide's current regulatory moment. The Journal covered the policy mechanism earlier this week: an administration plan that would let compounding pharmacies prepare BPC-157 and five other peptides without the FDA writing a new rule. What's new since then is a detailed look, published October 13 by KFF Health News and co-published by The Washington Post, at what the evidence for BPC-157 itself actually consists of — and at people who say they were harmed using it.

What BPC-157 is modeled on

BPC-157 is a synthetic fragment based on a protein sequence researchers identified in human gastric juice decades ago. In rodent studies, it's associated with promoting angiogenesis — new blood vessel growth — in damaged tissue, which is the proposed mechanism behind the healing effects reported in animal models of tendon, ligament, muscle, ulcer and skin injury. That same mechanism is why some researchers flag a theoretical cancer risk: a process that helps starved tissue regrow can, in principle, also feed a tumor. Nothing in the animal literature demonstrates that BPC-157 causes cancer in humans — the point researchers make is narrower: a mechanism linked to both healing and tumor growth hasn't been ruled out as a risk, because it hasn't been studied in people long enough to know.

What's actually known versus unknown

More than 150 published papers describe BPC-157 in animals, and the large majority trace back to one research group led by Predrag Sikiric in Zagreb, according to STAT/Undark's review of the literature. Sikiric is also listed on BPC-157 patent applications dating back decades and has ownership ties to companies with a commercial stake in the compound — conflicts the STAT/Undark review found undisclosed in the underlying papers.

Human evidence is much thinner. A 2015 oral-safety trial registered on ClinicalTrials.gov was tied to Sikiric's group; the team withdrew its submitted data before outside review and never published results. Two 2000s trials testing a BPC-157 enema for ulcerative colitis appear in no indexed, peer-reviewed publication. A Florida endocrinologist published three small studies, each with 2 to 16 participants and no control group. That's close to the entire published human record for a compound KFF Health News found more than 1,000 people had reported using.

What exists instead is a growing set of informal reports. The FDA's own adverse-event database includes a 36-year-old woman hospitalized after using BPC-157 for weight control and a skin condition, and a 48-year-old man hospitalized with what the report called a life-threatening condition. In July 2025, two women were intubated after receiving injections of experimental peptides at an anti-aging conference booth in Las Vegas; Nevada's pharmacy board later cited the doctor involved for practicing without a state license. KFF Health News also interviewed people reporting fatigue, anxiety, facial numbness and migraines after using BPC-157, including one man who described months of what he called "zero emotions" after nasal use. None of these reports, voluntary and unverified as they are, prove the peptide caused the symptoms — but they're also not nothing, which is exactly the problem researchers describe: there's no systematic human study designed to tell the difference.

Why it's being sold anyway

BPC-157 reaches people today mostly through two channels: online vendors labeling it "for laboratory research only, not for human consumption," and wellness clinics that have doctors prescribe it off a compounding pharmacy's shelf. Robert F. Kennedy Jr., the HHS Secretary, has called himself a "big fan" of peptides and has pushed to make them more accessible since taking office. An FDA advisory panel voted in July, 8-6 with one abstention, to recommend BPC-157 for the list of substances compounding pharmacies may legally prepare — a panel that included members with financial ties to the peptide industry, appointed shortly before the vote. FDA scientific staff had recommended against it, telling the committee they'd found only a handful of short, small human studies and no controlled trials at all.

The split wasn't close to unanimous even among panel members. Brian Lee, a University of Southern California liver specialist, voted no, saying he couldn't in good conscience vote yes on the evidence presented. Kris Wusterhausen, a Texas clinic founder, voted yes. Reshma Ramachandran, a Yale regulatory science researcher, told KFF Health News the incentives in how these products are sold "aren't actually centered around patients" — they're centered around selling products. That a committee weighing whether to expand access to a product included people positioned to profit from wider access is, depending on how charitably you want to read it, either an unavoidable feature of recruiting people who know the field, or not much of a surprise at all.

What this means for researchers

The honest accounting here has two separate parts that are easy to collapse into one. The animal data on BPC-157 is genuinely extensive — more than 150 papers, a real and long-running research program. What doesn't follow from that is any claim about what the compound does in a human body, because the step from promising rodent results to a demonstrated human effect fails far more often than it succeeds across drug development generally, and for BPC-157 specifically, that step has barely been attempted in a controlled way. A 2015 trial whose data was withdrawn before review isn't evidence either way; it's an absence.

The FDA's compounding-list vote doesn't resolve this gap — it reroutes around it. Moving BPC-157 from online gray-market sales to a compounding pharmacy's shelf changes who's legally allowed to prepare it, not what's known about what it does to the people taking it. Voluntary adverse-event reports and a handful of hospitalizations don't establish that the compound is dangerous, any more than the animal literature establishes that it's safe in people; both are signals pointing at the same hole, which is the absence of the randomized, controlled human trials that would actually answer the question.

Readers tracking the underlying biology can find background on BPC-157 and related compounds on Torrey Labs' compound guide. The regulatory and evidentiary questions covered here are separate from that: one is about who may legally prepare a peptide, the other is about what is actually known about taking it, and as this week's reporting shows, the second question is still barely answered.